JP2003527117A - Ｉｌ−１７レセプター様分子およびその使用 - Google Patents

Ｉｌ−１７レセプター様分子およびその使用

Info

Publication number
JP2003527117A
JP2003527117A JP2001567795A JP2001567795A JP2003527117A JP 2003527117 A JP2003527117 A JP 2003527117A JP 2001567795 A JP2001567795 A JP 2001567795A JP 2001567795 A JP2001567795 A JP 2001567795A JP 2003527117 A JP2003527117 A JP 2003527117A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
receptor
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001567795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003527117A5 (enExample
Inventor
シュキアン ジング，
ユージーン メドロック，
リチャード イエ，
スコット エム． シルビガー，
ギャリー エス． エリオット，
ハング キュー． ニューエン，
Original Assignee
アムジェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジェン インコーポレイテッド filed Critical アムジェン インコーポレイテッド
Publication of JP2003527117A publication Critical patent/JP2003527117A/ja
Publication of JP2003527117A5 publication Critical patent/JP2003527117A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001567795A 2000-03-16 2001-03-16 Ｉｌ−１７レセプター様分子およびその使用 Pending JP2003527117A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US18992300P 2000-03-16 2000-03-16
US60/189,923 2000-03-16
US20420800P 2000-05-12 2000-05-12
US60/204,208 2000-05-12
US72323200A 2000-11-27 2000-11-27
US09/723,232 2000-11-27
US26615901P 2001-02-02 2001-02-02
US60/266,159 2001-02-02
PCT/US2001/008688 WO2001068705A2 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2003527117A true JP2003527117A (ja) 2003-09-16
JP2003527117A5 JP2003527117A5 (enExample) 2008-04-24

Family

ID=27497823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001567795A Pending JP2003527117A (ja) 2000-03-16 2001-03-16 Ｉｌ−１７レセプター様分子およびその使用

Country Status (8)

Country Link
EP (1) EP1265924A2 (enExample)
JP (1) JP2003527117A (enExample)
AR (1) AR030554A1 (enExample)
AU (2) AU2001259029B2 (enExample)
CA (1) CA2401273A1 (enExample)
MX (1) MXPA02009024A (enExample)
TW (1) TWI322154B (enExample)
WO (1) WO2001068705A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523132A (ja) * 2010-03-30 2013-06-17 ヤンセン バイオテツク，インコーポレーテツド ヒト化ｉｌ−２５抗体
JP5561689B2 (ja) * 2007-11-28 2014-07-30 独立行政法人理化学研究所 Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2007202616B2 (en) * 2000-06-22 2011-08-18 Amgen Inc. IL-17 Like Molecules and Uses Thereof
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US20060142558A1 (en) * 2002-08-05 2006-06-29 Songqing Na Novel proteins and their uses
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2007117762A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
AU2007325520A1 (en) * 2006-10-13 2008-06-05 The Regents Of The University Of California Cancer treatment
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
GB0905972D0 (en) * 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
WO2000015759A1 (en) * 1998-09-16 2000-03-23 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
CA2067031C (en) 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
WO1994028122A1 (en) 1993-05-26 1994-12-08 Ontario Cancer Institute Transgenic mammals lacking expression of particular cd45 isoforms
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU705281B2 (en) 1994-12-23 1999-05-20 Uab Research Foundation Secreted human fas antigen
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
WO1997031898A1 (en) 1996-02-28 1997-09-04 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
CA2317817A1 (en) * 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
AU4201000A (en) * 1999-04-05 2000-10-23 Incyte Pharmaceuticals, Inc. Molecules of the immune system
WO2001057202A2 (en) * 2000-02-04 2001-08-09 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
TWI238191B (en) * 2000-02-08 2005-08-21 Amgen Inc IL-17 like molecules and uses thereof
US9100155B2 (en) 2010-05-03 2015-08-04 Qualcomm Incorporated Method and apparatus for control and data multiplexing in wireless communication
JP6160461B2 (ja) 2013-11-29 2017-07-12 富士通株式会社 尤度重み付け回路

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
WO2000015759A1 (en) * 1998-09-16 2000-03-23 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5561689B2 (ja) * 2007-11-28 2014-07-30 独立行政法人理化学研究所 Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法
JP2013523132A (ja) * 2010-03-30 2013-06-17 ヤンセン バイオテツク，インコーポレーテツド ヒト化ｉｌ−２５抗体

Also Published As

Publication number Publication date
AU2001259029B2 (en) 2006-01-05
TWI322154B (en) 2010-03-21
AU5902901A (en) 2001-09-24
EP1265924A2 (en) 2002-12-18
CA2401273A1 (en) 2001-09-20
MXPA02009024A (es) 2003-02-12
WO2001068705A3 (en) 2002-07-18
AR030554A1 (es) 2003-08-27
WO2001068705A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
US7943738B2 (en) IL-17 receptor like molecules and uses thereof
CA2412626C (en) Il-17 molecules and uses thereof
AU2001272968A1 (en) Il-17 molecules and uses thereof
AU2001259029B2 (en) Il-17 receptor like molecules and uses thereof
US20140037635A1 (en) Methods of treatment using il-17e antagonists
US20040048338A1 (en) IL-17 receptor like molecules and uses thereof
AU2001259029A1 (en) Il-17 receptor like molecules and uses thereof
JP2003520579A (ja) インターフェロン様分子およびその使用
JP2003523745A (ja) Ｉｌ−１７様分子およびその使用
AU2007202616B2 (en) IL-17 Like Molecules and Uses Thereof
JP2003516132A (ja) インターロイキン−１レセプターアンタゴニスト様分子およびその使用
JP2003516735A (ja) インターロイキン−１レセプターアンタゴニスト様分子およびその使用
JP2003518371A (ja) インターロイキン−１レセプターアンタゴニスト関連分子およびその使用
US20030099980A1 (en) IL-17 receptor like molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120131